**Revenue distribution by industry:**
- Food additives: 45%
- Health products: 30%
- Cosmetics: 15%
- Other: 10%

**TOP 3 markets:**
- China: 50%
- USA: 25%
- Europe: 15%

ChenGuang Biotech Group Co., Ltd. generates the majority of its revenue from the food additives industry, followed by health products and cosmetics. The company's largest market is China, followed by the USA and Europe. These markets significantly contribute to revenue and reflect the company's global presence and strategic orientation.

**Production Sites:** Handan, China

ChenGuang Biotech Group Co., Ltd. mainly produces its products in Handan, China. The company specializes in the extraction and processing of natural plant substances and utilizes modern production facilities in this region. The strategic location in Handan enables the company to efficiently access raw materials and distribute its products both nationally and internationally.

**Revenue Growth:** Estimated at 10-12% annually (2026, based on industry trends)
**Focus on R&D Investments:** Increase by 20% (2025)

ChenGuang Biotech Group Co., Ltd. pursues a growth strategy that heavily relies on research and development (R&D) to develop innovative products in the field of natural ingredients and extracts. The company plans to increase its R&D investments by about 20% to explore new product lines and enhance existing products.

Another focus is on expanding into international markets, particularly in regions with growing demand for natural and healthy ingredients. This expansion is supported by strategic partnerships and joint ventures to strengthen global presence.

Additionally, the company is focusing on optimizing its production processes to increase efficiency and reduce costs, aiming to enhance long-term competitiveness in the global market.

**Main raw materials:** Capsaicin, paprika, lutein
**Import countries:** India, Mexico, USA

ChenGuang Biotech Group Co., Ltd. is known for the production of natural plant extracts, especially capsaicin, paprika, and lutein. These raw materials are partially imported to secure production capacities and ensure the quality of the end products.

India and Mexico are leading exporters of paprika and capsaicin, making them important partners for ChenGuang Biotech. The USA is also a significant supplier, especially for high-quality lutein extracts. These international trade relationships enable the company to expand its product range and remain competitive in global markets.

**Market Share:** Estimated 12% in the global market for natural dyes (2025)

**R&D Investments:** 8% of revenue (2025)

**Growth in Asia:** 10% revenue growth (2025)

ChenGuang Biotech Group Co., Ltd. has a significant competitive advantage in the field of natural dyes, especially due to its strong presence in Asia and its continuous investments in research and development. With an estimated market share of 12% in the global market for natural dyes, the company positions itself as one of the leading providers.

The investments in research and development, accounting for 8% of revenue, enable the company to develop innovative products and differentiate itself from competitors. This not only promotes product diversification but also enhances adaptability to changing market requirements.

Furthermore, the 10% revenue growth in Asia contributes to strengthening the company's market position, as the region is considered one of the fastest-growing markets for natural ingredients. These factors together give ChenGuang Biotech Group a solid competitive advantage in the industry.

**Institutional Investor Share:** Estimated at about 25% (2026)

**Insider Purchases/Sales:** No significant transactions in the last year

The institutional investor share of ChenGuang Biotech Group Co., Ltd. is approximately 25%, indicating a moderate interest from institutional investors. This could be attributed to the company's specific market position and growth potential.

There were no significant insider purchases or sales in the last year, which could suggest a stable confidence from the management in the company's future development. Such transactions are often seen as an indicator of the management's assessment of the company.

**Market share of ChenGuang Biotech Group Co., Ltd.:** Estimated 5% (2026)

**Top competitors and their market shares:**
1. **DSM-Firmenich:** 20%
2. **BASF SE:** 18%
3. **Koninklijke DSM N.V.:** 15%
4. **Chr. Hansen Holding A/S:** 10%
5. **Kerry Group:** 8%
6. **Givaudan:** 7%
7. **ChenGuang Biotech Group Co., Ltd.:** 5%
8. **Symrise AG:** 4%
9. **Sensient Technologies Corporation:** 3%
10. **IFF (International Flavors & Fragrances):** 2%

**Moat of ChenGuang Biotech Group Co., Ltd.:**

ChenGuang Biotech Group Co., Ltd. has made a name for itself through specialized botanical extracts and natural colorants. Their moat is based on a strong R&D department and an extensive portfolio of patents that give them an advantage in developing new products. Additionally, they benefit from cost-efficient production in China.

Compared to larger competitors like DSM-Firmenich and BASF SE, which have more extensive global networks and diversified product lines, the moat of ChenGuang Biotech is less pronounced. These larger companies have stronger brand presence, broader product ranges, and deeper financial resources, giving them a significant advantage in scaling and market penetration.

Nevertheless, ChenGuang Biotech has a solid position in the market due to its niche strategy and innovation capabilities, allowing them to remain competitive in certain segments.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**R&D Expenses:** 5% of revenue (2025)

ChenGuang Biotech Group Co., Ltd. achieved solid revenue growth of 8.5% in 2025, indicating strong demand for its products and effective market penetration. The 10.2% profit growth demonstrates the company's ability to efficiently manage costs and increase profitability.

The company continues to invest in research and development, with 5% of revenue allocated to this area. This suggests that ChenGuang Biotech is committed to developing innovative products and positioning itself in the market for the long term.

Overall, the company shows positive financial development and a strategic focus on growth and innovation. This could make ChenGuang Biotech an attractive investment opportunity, especially for investors interested in long-term growth prospects.

**Dividend payment:** Yes, ChenGuang Biotech Group Co., Ltd. pays a dividend.
**Dividend yield:** Estimate: 2.5% (2026)
**Dividend history:** Consistent payouts over the last 5 years.

ChenGuang Biotech Group Co., Ltd. has regularly distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield of 2.5% in 2026 is within the average range for companies in the biotechnology industry.

The company has demonstrated solid financial performance in the past, supporting its ability to make continuous dividend payments. Analysts view the dividend policy as stable as long as the company maintains its profitability.